We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NIH Enrolls First Patients in COVID-19 Trial of Rigel’s Fostamatinib
NIH Enrolls First Patients in COVID-19 Trial of Rigel’s Fostamatinib
The NIH’s National Heart, Lung and Blood Institute (NHLBI) has enrolled the first participants in a multicenter phase 2 trial evaluating Rigel Pharmaceuticals’ oral spleen tyrosine kinase inhibitor fostamatinib as a COVID-19 treatment.